IMPACT BIOMEDICAL INC.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
IBO$4.62+6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025
| March 31, 2026 (unaudited) | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $20,000 | $3,000 |
| Accounts receivable | - | 5,000 |
| Inventory | 63,000 | 63,000 |
| Current portion of notes receivable | 199,000 | 198,000 |
| Prepaid expenses and other current assets | 95,000 | 142,000 |
| Total current assets | 377,000 | 411,000 |
| Other intangible assets, net | 16,709,000 | 16,994,000 |
| Total assets | $17,086,000 | $17,405,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $374,000 | $347,000 |
| Accrued expenses | 210,000 | 194,000 |
| Due to related party | 1,103,000 | 621,000 |
| Total current liabilities | 1,687,000 | 1,162,000 |
| Deferred tax liability, net | 688,000 | 688,000 |
| Total liabilities | 2,375,000 | 1,850,000 |
| Commitments and contingencies (Note 9) | - | - |
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 100,000,000 shares authorized, zero shares issued and outstanding on March 31, 2026 (zero on December 31, 2025); | - | - |
| Common stock, $0.001 par value; 4,000,000,000 shares authorized, 107,821,231 shares issued and outstanding on March 31, 2026 (104,621,231 on December 31, 2025) | 108,000 | 105,000 |
| Additional paid-in capital | 63,150,000 | 61,713,000 |
| Accumulated deficit | (51,794,000) | (49,507,000) |
| Total stockholders’ equity of the Company | 11,464,000 | 12,311,000 |
| Non-controlling interest in subsidiaries | 3,247,000 | 3,244,000 |
| Total stockholders’ equity | 14,711,000 | 15,555,000 |
| Total liabilities and stockholders’ equity | $17,086,000 | $17,405,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.